Press

Cite us, and check us

eDietAdvice maintains verified pricing across the GLP-1, ED, hair, skin, and longevity markets — 18 channels, 40 monitored pricing pages, weekly automated diffs, public changelog. Journalists get the dataset free and our error-correction is public.

Citable facts (each carries sources on its page)#

The same Wegovy pill lists at $149/month from the manufacturer's pharmacy and ~$298 effective at major telehealth brands once required ~$149/month memberships are counted — the membership-fee analysis.
Legal 503A compounded semaglutide currently runs ~$139–$297/month all-in across the market we track — the surviving market, priced.
Generic sildenafil spans $0.22 to $10 per equivalent dose across legitimate channels — the ED tables.
The finasteride in a $25/month subscription costs $0.83/month at itemized generic pricing — the markup exhibit.
Six peptides including BPC-157 were PCAC-recommended for the 503A list in July 2026, over FDA staff objections, final FDA action pending — the Legal-Status Tracker.
41 of the 97 FDA-registered 503B outsourcing facilities — 42% — have never been inspected by the FDA. Parsed from FDA's own registry, which publishes no download — the pharmacy index.
Of the 10 compounding pharmacies named in connection with the channels we track, only 2 appear on any federal register. The rest are 503A pharmacies, which FDA does not register or publish — their oversight is a state board and there is no federal inspection record to look up — the named-pharmacy index.
The compounding pharmacy Hims names in its own 10-K, MedisourceRx, carries a Form 483 and an FDA Warning Letter issued 12 December 2025 — cross-checked against FDA's 503B register.
Only 3 of 9 telehealth providers selling compounded GLP-1s name the pharmacy that makes the medication. In several cases the pharmacy became public only because a manufacturer named it in a lawsuit — the disclosure table.
Three of 15 providers we profile disclose no legal entity, address, leadership or ownership at all — the transparency scorecard.
Of 71 active FDA ingredient-supplier filings for semaglutide, 56 are Chinese (79%); for tirzepatide it is 32 of 38 (84%). For older molecules the pattern reverses — 13 of 17 sildenafil filings are Indian — the manufacturing investigation.
Eli Lilly's FY2025 accounts show it spent marginally more on marketing, selling and admin ($11.09B) than on manufacturing everything it sold ($11.05B) — audited figures, sourced.
Removal from the FDA's peptide Category 2 list conferred no compounding eligibility: the 12 peptides removed in April 2026 sit on no list at all, which carries no enforcement discretion. Exactly one of the original 19 — GHK-Cu, non-injectable only — can lawfully be compounded today — why the reporting got this wrong.
Three of the seven peptides an FDA advisory committee reviewed in July 2026 — KPV, TB-500 and MOTS-c — have never been administered to a human in any published study of any design — FDA's own systematic reviews.

Every figure above is dated and linked to a primary source on its own page. If one of them is wrong we want to know, and the fix appears in our public corrections log.

The data#

Machine-readable, CC BY 4.0, verification dates on every row: /api/. Reuse it commercially with attribution.

Put the table in your piece. One div and one script tag renders a live price table on your own page. No key, no rate limit, no tracking of your readers, and it updates itself when our figures change — so a story published today does not carry last month's prices in six months' time.
Check what moved. Every change to a tracked price is appended to the price history with the date it was verified and the provider page it came from. Useful if you need to say what something cost before.
See who makes it. The pharmacy index carries all 10 compounding pharmacies named in connection with the channels we track, what kind of evidence names each one — an SEC filing, a court record, a marketing page — and whether they appear on FDA's 503B register.

Fact-checks and corrections#

Checking a number across every channel takes us minutes — a press contact address goes live with launch. When we're wrong, the correction is public: it lands in the changelog, dated.

About the operation#

Independent publication; nobody pays for placement; rankings are ordered by verified cost. The cheapest channels in our index pay us nothing and top the tables anyway — the methodology is the whole story.